Scottsdale Healthcare
Research Institute
Scottsdale Healthcare is one of the southwest’s leading health systems, recognized for its medical innovations and superior personalized patient care. That same commitment to personalized care holds true for patients seen in clinical trials at the Scottsdale Healthcare Research Institute.
Physicians and scientists at the Scottsdale Healthcare Research Institute collaborate with leading research universities and benefit in their unique personalized medicine approach by a strategic alliance with the Translational Genomics Research Institute (TGen), a world leader in developing smarter treatments for complex diseases. Scottsdale Healthcare is a primary clinical research site for TGen, providing patients with access to cutting edge technologies.
Participate in Clinical Trials:
Through this alliance, patients with cancer have the opportunity to participate in clinical trials of revolutionary cancer treatments.
In the past, these clinical trials were considered a last resort. Today, patients with cancer may have the option to receive their first treatment in a clinical trial. Evidence shows that patients who participate in clinical trials often benefit more than those who do not.
Our clinical trials also provide the vital information needed to advance medical care and bring effective medicines from the laboratory bench to the patient's bedside as quickly as possible.
Our World-renowned Cancer Physician and Researcher:
Scottsdale Healthcare Research Institute’s cancer program is led by world-renowned cancer physician and researcher Daniel D. Von Hoff, MD, FACP and is located in the Debi & Jerry Bisgrove Research Pavilion at Scottsdale Healthcare. Dr. Von Hoff is Chief Scientific Officer for Scottsdale Healthcare Research Institute, and Distinguished Professor and Physician-in-Chief at TGen.
Research That Earns Recognition:
Our work to develop new and innovative therapies for improving the health and quality of life of cancer patients has not gone unnoticed.
- Results of a breakthrough clinical trial at the Virginia G. Piper Cancer Center were featured in the New England Journal of Medicine, which reported that a drug called GDC-0449 shows tumor shrinkage and limited side effects in patients with advanced and metastatic basal cell skin cancer and other cancers. The findings are significant because there is no proven therapy for advanced basal cell carcinoma.
- The Virginia G. Piper Cancer Center, through its strategic alliance with TGen, co-leader of the $18 million Stand Up to Cancer Study to investigate new approaches to treating pancreatic cancer.
- Researchers at the Virginia G. Piper Cancer Center identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy. The discovery is critical because patients with small-cell lung cancer often do not get a second chance at therapies to combat the aggressive form of cancer.
- We were the first site in the world for clinical trials of a drug called OSI-906 to combat adrenocortical carcinoma, a rare but deadly cancer that attacks the adrenal glands.
- We were the world's first clinical trials site for NMS-1286937, a new drug designed to stop cancer from spreading by preventing the process of cell division.
- We were the first site in the world to administer ASG-5ME, a new investigational drug designed to penetrate and attack pancreatic cancer cells.
Contact Us:
Our Cancer Care Coordinators will be your personal advocate, serving as a link between you, your physicians and the clinical trials team to ensure youi have the education, support and resources that you need.
For additional information about clinical trials available through Scottsdale Healthcare Research Institute, contact the Cancer Clinical Trials Coordinator at 480-323-1339 (toll free: 1-877-273-3713),
or e-mail clinicaltrials@shc.org.